Roivant Sciences is trading 13.46% up now at $39.63 after positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease.
- The 135-patient study showed a statistically significant 56% placebo-adjusted reduction in pulmonary vascular resistance, alongside improvements in walking distance and NT-proBNP.
- The company presented the data on September 8, 2026, at the ERS Congress, driving strong biotech trading activity.